Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study

Diabetes Research and Clinical Practice
Marina GradišerInes Bilić-Ćurčić

Abstract

We included diabetes type 1 (T1DM) patients with suboptimal glycemic control on morning application glargine (I-Glar) U100, switching them to U300. After six months improvement in HbA1c was observed, while hypoglycemic episodes decreased. Switch from I-Glar U100 to U300 could be a good therapeutic option for that subset of patients.

Citations

Sep 18, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Vincent WooRobert Roscoe
Jul 31, 2018·Expert Review of Endocrinology & Metabolism·Philippe OriotMartin Buysschaert
Mar 28, 2021·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Florentino Carral San LaureanoMaría Del Carmen Ayala Ortega

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Related Papers

Diabetes Technology & Therapeutics
John B Williams
Journal of Clinical Research in Pediatric Endocrinology
Hyuntae KimPaul B Kaplowitz
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association
A ToneK Shikata
© 2022 Meta ULC. All rights reserved